All lobbying filings

FOUNDATION MEDICINE, INC.

Lobbying for FOUNDATION MEDICINE, INC.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $80,000.00 expenses · posted Jul 18, 2025

Official filing document

Bills named in this filing 3

HR 5377
Cancer Patient Equity Act of 2021
HR 2369
PHIT Act of 2025
HR 3561
FORCE Act

Lobbying activity 1

Health Issues

- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.